title: [Clinical study of terodiline hydrochloride for the treatment of urinary frequency and urinary incontinence, and its cardiovascular adverse effects].
abstract: We evaluated the effectiveness and side effects of terodiline hydrochloride in 109 patients with urinary frequency and urinary incontinence. The drug was administered at a dose of 24 mg once a day or 12 mg twice a day for 4 weeks. Symptoms such as urinary frequency and urinary incontinence were alleviated in 101 out of 109 patients (92.7%). Mild side effects such as thirst, dysuria, sense of residual urine, orthostatic hypotension and arrhythmia were observed in 9 out of 109 patients (8.2%). Side effects such as orthostatic hypotension and arrhythmia were observed on the 28th day or the 20th day of the administration, but these symptoms disappeared with discontinued use of this medicine. The results obtained from this study suggest that terodiline hydrochloride may be greatly useful for the patients with urinary frequency and urinary incontinence. But we must take account of the side effects such as orthostatic hypotension and arrhythmia.
authors.affiliation: Department of Urology, Osakay City University Medical School.
authors.forename: H
authors.initials: H
authors.lastname: Yoshihara
authors.forename: R
authors.initials: R
authors.lastname: Yasumoto
authors.forename: T
authors.initials: T
authors.lastname: Kishimoto
authors.forename: M
authors.initials: M
authors.lastname: Maekawa
authors.forename: A
authors.initials: A
authors.lastname: Horii
authors.forename: T
authors.initials: T
authors.lastname: Nishijima
authors.forename: T
authors.initials: T
authors.lastname: Sugimoto
authors.forename: N
authors.initials: N
authors.lastname: Kashiwara
authors.forename: M
authors.initials: M
authors.lastname: Tsujita
authors.forename: M
authors.initials: M
authors.lastname: Senjyu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D002082:Butylamines / Q000009:adverse effects / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000009:adverse effects / Q000627:therapeutic use*; D014549:Urinary Incontinence / Q000188:drug therapy*; D014555:Urination Disorders / Q000188:drug therapy*
chemical_list: D002082:Butylamines; D002121:Calcium Channel Blockers; D010276:Parasympatholytics; C010637:terodiline